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Whole genome expression microarrays can be used to study gene expression in blood, which
comes in part from leukocytes, immature platelets, and red blood cells. Since these cells are
important in the pathogenesis of stroke, RNA provides an index of these cellular responses to
stroke. Our studies in rats have shown specific gene expression changes 24hours after ischemic
stroke, hemorrhage, status epilepticus, hypoxia, hypoglycemia, global ischemia, and following brief
focal ischemia that simulated transient ischemic attacks in humans. Human studies show gene
expression changes following ischemic stroke. These gene profiles predict a second cohort with
>90% sensitivity and specificity. Gene profiles for ischemic stroke caused by large-vessel
atherosclerosis and cardioembolism have been described that predict a second cohort with
>85% sensitivity and specificity. Atherosclerotic genes were associated with clotting, platelets, and
monocytes, and cardioembolic genes were associated with inflammation, infection, and neutrophils.
These gene profiles predicted the cause of stroke in 58% of cryptogenic patients. These studies will
provide diagnostic, prognostic, and therapeutic markers, and will advance our understanding of
stroke in humans. New techniques to measure all coding and noncoding RNAs along with
alternatively spliced transcripts will markedly advance molecular studies of human stroke.
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Introduction—blood and blood vessels
in stroke
Ischemic stroke, in most cases, is a disease of the
vasculature and blood, involving platelets, red blood
cells, clotting factors, inflammatory cells, and en-
dothelium. Though the result is ischemic brain
damage, the primary disease process does not
generally relate to the brain tissue itself except in
some diseases such as mitochondrial diseases. Most
strokes in humans are due to large-vessel athero-
sclerotic disease, cardioembolic disease (blood
clots), and lacunar small vessel disease (Amarenco
et al, 2009). Atherosclerosis is an inflammatory
disease due to a complex interaction between lipids,
endothelium, and vascular risk factors (Chalela,
2009; Chamorro and Hallenbeck, 2006; Hansson,
2009). Atherosclerotic plaques cause stroke by
thromboembolism of clot/platelets formed at the
plaque or following plaque fragmentation (Chalela,
2009; Wu and Grotta, 2010). Cardioembolic stroke
represents a group of cardiac disorders with a
propensity to form blood clots in the heart that
embolize to brain (Babarro et al, 2009). The third
major stroke subtype, lacunar, is due to ‘lipohyali-
nosis’ of small penetrating vessels in the brain (Nah
et al, 2010; Stevenson et al, 2010).
Thus, studies of blood cells and vessels are very
relevant for understanding all subtypes of ischemic
stroke. The role of the immune system has also
gained more attention based upon human and animal
studies. The importance of the immune system in
human stroke was emphasized by the Enlimomab
trial, which worsened outcome. In a follow-up animal
study it was found that the deleterious effect of the
murine anti-intercellular adhesion molecule 1 (ICAM-
1) antibody was probably due to the augmentation of
ischemic brain injury by the immunogenicity of the
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considered a ‘negative’ trial, this trial does point out
the great importance of the immune system involve-
ment in human ischemic stroke (Furuya et al, 2001).
An increasing number of animal studies demonstrate
the role of inflammatory cytokines, chemokines,
neutrophils, lymphocytes, monocytes, and a variety
of other immune molecules including toll receptors
in modulating stroke outcome (Becker, 2010; Cha-
morro and Hallenbeck, 2006; del Zoppo, 2010;
Downes and Crack, 2010; Elkind, 2010; Hallenbeck,
2010; Marsh et al, 2009). These studies prompted our
studies of gene expression in blood to evaluate
cerebrovascular diseases.
Markers for stroke assessed from blood
A benefit of studying blood is that one could
potentially derive biomarkers of stroke to facilitate
diagnosis, determine cause, offer prognostic informa-
tion, and provide insight into pathogenesis and
prevention. A number of potential biomarkers have
been examined including proteins, peptides, cyto-
kines, chemokines, metabolites, leukocytes, platelets,
stem or progenitor cells, microparticles, and others
(Jickling et al, 2009; Reid et al, 2010). Most studies
have examined serum or plasma. The goal of many
studies has been to search for proteins released from
injured neurons, glia, or endothelial cells that could be
used as indicators of tissue damage. These molecules
are the subject of a number of recent reviews (Chavez
et al, 2009; Dassan et al, 2009; El Husseini and
Laskowitz, 2010; Elkind, 2009; Foerch et al, 2009;
Jensen et al, 2009; Montaner, 2009; Saenger and
Christenson, 2010; Whiteley et al, 2009a,b).
This review will focus primarily on RNA expres-
sion in blood following stroke (Sharp et al, 2006).
The rationale for examining RNA is outlined below,
followed by proof-of-principle studies in animals
that formed the basis for subsequent human studies.
This review will mainly summarize our own studies
and those most related to them. This is done because
it is difficult to compare between platforms and
using different approaches for isolating cells and
isolating RNA. We recommend other studies as a
contrast to our own since most support the same
proof-of-principles even if the same molecules were
not always identified (Baird, 2006, 2007; Barr et al,
2010; Carmichael, 2003; Freedman et al, 2010;
Grond-Ginsbach et al, 2008, 2009; Kassner et al,
2009; Li et al, 2010; Ridder et al, 2009).
Advantages of RNA and microarrays
RNA was studied for several reasons. RNA is
induced extremely rapidly (within minutes) well
before events could be detected using protein
markers. Second, almost all of the currently known
coding RNAs have been described and are available
on a single platform (Alizadeh et al, 2000). This
provides a major advantage over many protein
biomarker studies. Using arrays of all known RNAs
allows one to derive ‘the best’ markers rather than
prospectively guessing at what the best biomarkers
might be (Tang et al, 2001, 2002, 2005).
The approaches for identifying proteomic markers
are quite different (Zhang et al, 2008). The most
common approach uses candidate protein biomar-
kers, which may or may not be the best. Alternative
proteomics approaches use mass spectrometry and
some sort of preselection, which usually assesses
only part of the proteome (Yao et al, 2009). However,
protein biomarkers for vasospasm after subarachnoid
hemorrhage have been discovered using this
approach (King et al, 2010; Maurer et al, 2007, 2008).
Mass spectrometry offers the advantage of being able
to examine protein modifications and isoforms.
However, newer RNA technologies are making it
possible to also examine alternative splicing using
exon arrays or high-throughput RNA sequencing.
One potential advantage of identifying RNAs that
are regulated in stroke is that these might serve to
guide the search for similarly regulated proteins.
However, this may not be desirable. First, some
RNAs do not code for proteins. Second, the synthesis
of some RNAs does not result in a corresponding
change of protein synthesis. Third, the RNAs usually
represent intracellular molecules, with the possible
exception of some microRNAs, most of which are not
secreted from the leukocytes, platelets, and red blood
cells. Thus, RNA itself might be preferable for some
indications like studying the immune response, and
proteins would be preferred for other indications like
injury to endothelium, glia, and neurons.
Disadvantages of RNA and microarrays
Studying RNA in blood of stroke patients has been
challenging. Fold changes of expression are usually
less than twofold, making detection of biological
effects difficult. At present, studies of whole blood
are the most feasible and thus lose specificity related
to responses of specific cell types. This is because we
use special vacutainer tubes to obtain whole blood
via venipuncture, which lyse all cells and immedi-
ately stabilize released RNA. This is essential since
RNA is unstable and rapidly degrades unless
stabilized. The other disadvantage of RNA is that it
can be slow to measure—requiring arrays, reverse
transcriptase polymerase chain reaction (PCR), or
blots. This may be resolved in part by attempts at
developing point of care PCR (Lee et al, 2010).
Why study leukocyte RNA in blood of
stroke patients
A conceptual issue in the field has been how
leukocytes can report on or respond to brain
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leukocytes patrol the body, interact with cells from
every tissue, endothelial cells of the vasculature,
foreign organisms or cells, injured cells and every
element within blood (Franks et al, 2010). In
addition, leukocytes have a complement of ex-
pressed RNAs that reflect a combination of the
genetics of these cells as well as the interactions of
those cells with their environment.
In Figure 1, we show an overview of how
leukocytes might respond to cues relevant to stroke
in humans. Leukocytes of all types express various
adhesion molecules on their surface and interact
with normal or inflamed endothelium (Figure 1)
(Pries and Kuebler, 2006). Thus, injured brain signals
to endothelium to express different adhesion mole-
cules on the luminal side of the vessel, which in turn
signal to leukocytes (Beck et al, 1997). Leukocytes in
blood are known to interact with both platelets and
elements of the atherosclerotic plaque and may
contribute to disease (Caplan and Fisher, 2007;
Franks et al, 2010; Htun et al, 2006). Thus,
endothelial cell–platelet interactions signal to leu-
kocytes and endothelial cell–atherosclerotic plaque
interactions signal to leukocytes (Clark et al, 1993).
Moreover, blood clots that form in the heart or other
sites are detected by circulating leukocytes. In
addition, the platelets and clots that form on
atherosclerotic plaques interact with leukocytes,
which may contribute to instability of the potentially
embolic elements (Akopov et al, 1996). Finally,
leukocytes independent of the above influences
respond to cytokines, chemokines, hormones, and
other molecules in blood, which differ as a function
of the genetics of each individual cell and their
environment (Figure 1). Indeed, each of the above
leukocyte interactions results from a complex inter-
play of the individual environmental interactions of
each cell and the genetic make up of the cells
(Elneihoum et al, 1996). Thus, though leukocytes
themselves do not cause strokes, they can sense and
likely have specific intracellular signaling related to
the main causes of stroke. The rapidly growing
literature on the immune response to stroke and
associated signaling events is beyond the scope of
this review.
Animal studies—focal ischemia,
hemorrhage, seizures, hypoxia,
hypoglycemia
Even assuming leukocytes detect all of the events
pictured in Figure 1, we initially had no idea
whether there would be enough reactive leukocytes
in blood that could be detected by taking a single
blood sample from an animal or human at a single
point in time. After all, there are hundreds of
thousands of leukocytes in peripheral blood only a
fraction of which might respond to factors related to
stroke, potentially making it difficult or impossible
to detect RNA changes in the few leukocytes
collected in a single blood sample. To address this
question, we performed the first study of its kind
using several different experimental brain injury
models in rats (Tang et al, 2001).
Adult rats were subjected to experimental is-
chemic strokes, hemorrhagic strokes, kainic acid-
induced status epilepticus, insulin-induced hypo-
glycemia, or hypoxia and compared with sham-
operated controls and to untouched, naive controls
(Tang et al, 2001). At 24hours, RNA from peripheral
blood monocytes (PBMCs) was processed on Affy-
metrix microarrays. There were hundreds of upregu-
lated and downregulated genes for each condition
compared with sham or untouched controls
(Figure 2A). This study demonstrated that (1) there
were detectable changes of gene expression in blood
24hours after each injury; (2) no single gene was
specific for a given injury; and (3) there were groups
or ‘profiles’ of genes that distinguished each condi-
tion from the other (Tang et al, 2001) (Figure 2A).
Though there were genes shared by every injury,
perhaps related to stress or similar mechanisms of
injury, there were profiles specific for the injury
(Figure 2B). Comparisons of expression using arrays
(Figure 2B, teal) and PCR (Figure 2B, blue) showed
very similar patterns for each even in these early
studies (Figure 2B), which has been validated in
many studies since that time (Git et al, 2010;
Mieczkowski et al, 2010).
These studies provided the first proof-of-principle
that gene expression in blood changed 1 day
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Figure 1 Leukocyte interactions with intravascular elements
relevant for stroke in humans. Leukocytes (neutrophils, lympho-
cytes, monocytes), platelets, red blood cells, and other cells
interact with each other and with endothelial cells in normal
vessels. Leukocyte interactions with endothelial cells, platelets,
atherosclerotic plaque, blood clots, and intravascular molecules
(cytokines, chemokines, hormones, others) likely account for
some changes of gene expression following stroke. Leukocytes
also signal to these other cell types, which also account for
changes of gene expression.
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bolic stresses like hypoxia and hypoglycemia (Tang
et al, 2001). The studies also showed that different
types of brain injury were associated with specific
gene expression profiles in blood. In a follow-up
study we demonstrated that there were specific gene
profiles in brain for each of these injuries as well
(Tang et al, 2002). Just as in the blood, there were
genes that were common to all of the injuries and
could represent responses to stress, neuronal injury,
or death and other factors common to each condition.
Though many genes expressed in blood were also
expressed in brain, the majority were different (Tang
et al, 2002). Thus, one cannot necessarily use blood
to infer changes of gene expression in brain.
Animal studies—injury (neuronal cell
death) versus no injury
We next determined whether there might be a profile
for ‘neuronal injury.’ Global ischemia was produced
by bilateral carotid occlusion in rats, which resulted
in no cell death in some animals and cell death in
hippocampus and cortex documented with terminal
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Figure 2 Animal studies of gene expression in blood following cerebral ischemia and other injuries. (A) Cluster plot of gene
expression in blood of adult rats 24hours following sham operation (S), suture-induced brain ischemia stroke (BI), brain hemorrhage
(BH), kainate-induced status epilepticus (K), hypoxia (H), and insulin-induced hypoglycemia (IG) compared with controls (C).
Increased gene expression is shown in red and decreased gene expression is shown in deep green. (B) Comparison of gene expression
in the experiments in ‘A’ using microarrays (teal) and reverse transcriptase polymerase chain reaction (RT-PCR) (blue). Data for three
genes are shown for the seven different experimental conditions: C, S, BI, BH, K, H, and IG. Abbreviations are given in ‘(A).’ (C) Adult
rats were subjected to global cerebral ischemia using the two-vessel occlusion model. RNA from blood was examined 24hours later
and brain injury was assessed using both terminal deoxynucleotidyl transferase-mediated 2’-deoxyuridine 5’-triphosphate-biotin nick
end labeling (TUNEL). There were genes differentially regulated in the two groups, which completely separated these animals on this
cluster analysis. (D) Gene expression was assessed in blood of adult rats 24hours following 5, 10, and 120minutes of focal cerebral
ischemia using the suture/thread technique. Genes were discovered that were distinct for each duration of occlusion—5, 10, and
120minutes. Thus, the 5- and 10-minute duration of focal ischemia that mimic human transient ischemic attacks (TIAs) produce
unique changes of gene expression in blood 24hours after the events. This figure is adapted from several publications (Tang et al,
2001, 2003; Zhan et al, 2010).
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dine 5’-triphosphate-biotin nick end labeling (Tang
et al, 2003). Blood obtained from these animals
24hours later showed 37 upregulated and 67 down-
regulated genes in the ‘injury’ animals compared
with the ‘no injury’ animals (Figure 2C). These data
were important for showing that gene expression
changes were detectable even when there was
selective neuronal cell death (Tang et al, 2003).
Animal studies—transient focal
cerebral ischemia
Recent studies have also shown changes of gene
expression in blood of rats following brief periods of
focal ischemia that mimic human transient ischemic
attacks (Zhan et al, 2008, 2010). Adult rats were
subjected to sham operations or 5 minutes, 10min-
utes, or 2hours of middle cerebral artery ischemia
using the suture model. Hsp70 protein was induced
24, 48, and 72hours later in neurons throughout the
middle cerebral artery territory. Following 5 and 10
minutes middle cerebral artery occlusions, 9 of 32
animals (28%) had microinfarcts in striatum (Zhan
et al, 2008). These studies showed that brief ischemia
in animals can be associated with microinfarcts in
some animals. Moreover, there was a stress gene
response in the ‘penumbra’ in brain as manifested by
induction of Hsp70 protein in the middle cerebral
artery distribution. We postulated that these mole-
cular responses in brain would be associated with
molecular responses of circulating leukocytes (Zhan
et al, 2008).
To test this, the identical study was performed
except that whole blood was obtained at 24hours
following 5, 10, or 120minutes of focal cerebral
ischemia (Zhan et al, 2010). These studies showed
genes regulated in blood that were specific for 5, 10,
and 120minutes of focal ischemia (Figure 2D).
Moreover, there were 103 genes common to brief
focal ischemia and ischemic stroke (Zhan et al,
2010). The data confirm immune responses to
brain that may not be associated with cell death.
The nature of this ‘sublethal’ signaling is less clear
but might include cytokines and chemokines
that could signal from brain to blood and blood to
brain.
Human studies—first study assessing
diagnosis of ischemic stroke (2005)
The first human study to assess RNA expression in
stroke was published by the Baird group (Moore et al,
2005). Using PBMCs obtained 1 to 4 days following
ischemic stroke, 190 genes were significantly regu-
lated in 20 stroke compared with 20 control subjects
(Moore et al, 2005). A panel of 22 genes derived from
the prediction analysis for microarrays algorithm in
the index cohort (n=40) classified stroke in the
validation cohort (n=20), with a sensitivity of 78%
and a specificity of 80%. These findings were
extremely important because they used the genes in
one cohort to predict stroke in a second cohort—
supporting the validity of the findings within this
study (Moore et al, 2005); supporting the proof-of-
principle in our previous rodent studies (Tang et al,
2001). Notably, even though virtually identical
methods were used in our prior rodent study (Tang
et al, 2001) compared to this human study (both used
PBMCs and Affymetrix arrays), very few genes were
similarly regulated in the blood of rats (Tang et al,
2001) compared to the humans with ischemic strokes
(Moore et al, 2005). The explanation for this is
unclear but is reviewed elsewhere (Turner et al,
2011a). It is possible that the experimental methods
of producing ischemia (suture methods, anesthesia,
young animals with no vascular disease) in animals
simply results in different gene expression responses
compared with stroke in humans; or the immune
responses in rodents may be different in humans
following ischemic stroke. These and other possibi-
lities need further study since they are relevant to
understanding how well animal stroke studies
‘model’ human stroke.
Human studies—whole genome, whole
blood studies of ischemic stroke
In our initial rodent study (Tang et al, 2001), and in
the first human study (Moore et al, 2005) blood was
drawn and then PBMCs were separated from the
blood using a Ficoll gradient and centrifugation. This
procedure in and of itself could affect gene expres-
sion in blood. If performed at different times after
stroke, or if the methods were not identical, this
could affect gene expression.
We therefore utilised PAXgene tubes to address
this issue. These commercial vacutainer tubes lyse
cells and stabilize RNA, and have proven to be
reliable for many clinical studies (Chai et al, 2005;
Thach et al, 2003; Vartanian et al, 2009; Yamamoto
et al, 2006). Blood from 15 patients was drawn into
PAXgene tubes at <3, 5, and 24hours after ischemic
stroke (n=45 samples) and compared with 14 control
samples (Tang et al, 2006). RNA processed on
Affymetrix U133 microarrays showed that over
1,000 genes were upregulated or downregulated in
the blood of ischemic stroke compared with control
subjects (Figure 3). Most of the genes expressed at 2
to 3hours after stroke (before treatment) were also
expressed at 5 and 24hours after the strokes (Tang
et al, 2006). Prediction analysis of microarrays
derived the 25-probe sets for 18 genes that were
most predictive of stroke (Figure 3). The fold change
of these genes varied from 1.6 to 6.8 and these genes
correctly classified 10/15 patients at 2.4hours, 13/15
patients at 5hours, and 15/15 patients at 24hours
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this study were compared with the previous study
from Moore et al, however, there were very few genes
that were common to both. The explanations for
these differences probably included bloods were
drawn at different times after the stroke; differences
in treatment; the use of PBMCs for the Moore et al
study and the use of whole blood/PAXgene tubes for
the Tang et al study; and the use of different RNA
isolation and labeling methods and the use of
different arrays for the two studies.
To address the issue of reproducibility, we have
recently repeated our initial study in a larger cohort
(Stamova et al, 2010). Thus, patients with ischemic
stroke (n=70, 199 samples) were compared with
control subjects who were healthy (n=38), controls
with vascular risk factors (n=52), and to subjects
who had myocardial infarction (n=17). Whole blood
was drawn into PAXgene tubes at p3, 5, and
24hours after stroke onset and RNA processed on
whole genome Affymetrix U133 microarrays. The 25-
probe sets previously reported in our study by Tang
et al predicted a new set of ischemic strokes with
93.5% sensitivity and 89.5% specificity. In order to
derive profiles that would distinguish ischemic
stroke from all control subjects, we derived 60- and
46-probe sets that differentiated control groups from
3 and 24 hours ischemic stroke samples, respectively
(Table 1). Thus, this study replicated our previously
reported gene expression profile in a larger cohort
Figure 3 Gene expression in whole blood of humans following ischemic stroke. Patients had whole blood drawn before 3hours after
an ischemic stroke and before treatment with tissue plasminogen activator (tPA) with or without eptifibatide. Blood samples from the
same patients were drawn again at 5 and 24hours. RNA from these samples was processed on whole genome microarrays. When
comparing ischemic stroke to control patients, over 1,000 genes were regulated in blood (B). Using prediction analysis of
microarrays, the optimal set of genes (n=18) were derived that best distinguished ischemic stroke patients from controls (A). This
figure is adapted from Tang et al (2006).
Table 1 Sensitivity and specificity of diagnosing ischemic stroke (n=199) versus controls (n=90)
Group 60 Probe sets 3hours
ischemic stroke versus controls
46 Probe sets 24hours ischemic
stroke versus controls
97 Probe sets 3 and 24hours ischemic
stroke combined versus controls
PAM SVM PAM SVM PAM SVM
IS 85% 94% 91% 94% 86% 95%
SAVVY 92% 96% 92% 96% 96% 96%
Healthy 84% 68% 89% 84% 84% 68%
IS, ischemic stroke; PAM, prediction analysis of microarrays; SAVVY, vascular risk factor controls; SVM, support vector machine prediction algorithm.
This is taken from Stamova et al (2010).
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ischemic stroke from relevant control groups (Sta-
mova et al, 2010).
Finally, another recent study from Barr supports
the above findings. Whole blood was obtained in
PAXgene tubes from 39 ischemic stroke patients and
25 healthy control subjects (Barr et al, 2010). RNA
was processed on Illumina HumanRef-8v2 bead
chips. Among a large number of regulated genes,
they identified a nine-gene profile that separated
ischemic stroke patients compared with controls
(Barr et al, 2010). Moreover, five of these nine genes
were identified in our previous study (Tang et al,
2006). Thus, another group has confirmed at least a
core set of genes, and we have replicated our own
gene expression studies following ischemic stroke.
All of these studies, however, are confounded to
some degree by various treatments, comparisons to
healthy controls, variations in time after stroke,
different risk factors between groups and differences
of age, race, and gender. Nonetheless, the first test of
the technology has been achieved: replication of
results and independent validation by at least two
different groups. Such promising results provide
strong support for further study.
Causes of stroke in humans—large
vessel and cardioembolic
Early on it was apparent that developing a
‘diagnostic test for stroke’ would be difficult, and
perhaps not of practical use unless it could be
performed within the first few hours of stroke. In
addition, a diagnostic test would not only have to
diagnose ischemic stroke but rule out hemorrhagic
stroke if it were used to guide acute stroke treatments
such as tissue plasminogen activator (tPA).
Thus, we have approached different questions that
could be rapidly translated to the care of stroke
patients. We asked whether gene profiles in blood
exist that are specific for the different causes of
ischemic stroke. The main reason for developing
such profiles would be to use them to diagnose the
cause of ischemic stroke in those patients with
‘cryptogenic stroke’ with no known cause who
represent approximately one third of all ischemic
strokes.
In the first study, whole blood was collected in
PAXgene tubes from acute ischemic stroke patients
(<3, 5, and 24hours) and healthy controls. RNAwas
isolated and processed on Affymetrix Human U133
Plus 2.0 Arrays. Expression profiles in the blood of
cardioembolic stroke patients differed from large-
vessel atherosclerotic stroke patients (Figure 4). Of
the 77 genes that differed between the two groups
(fold change >1.5, P<0.05), a minimum number of
23 genes differentiated the two types of stroke with
>90% specificity and sensitivity (Xu et al, 2008).
Notably, some of the genes that distinguished
cardioembolic from atherosclerotic stroke displayed
little change over time (Figure 4). These might be
genes expressed differentially prior to stroke—and
perhaps indicate risk of stroke. Other genes dis-
played significant change over time, suggesting that
these time-dependent alterations in gene expression
were associated with differential gene expression of
immune cells due to the strokes caused by cardio-
embolism compared with atheroembolism (Figure 4)
(Xu et al, 2008).
We have recently confirmed these initial findings
using identical methods to study 194 samples from
76 acute ischemic stroke patients (Jickling et al,
2010). A 40-gene profile differentiated cardioembolic
stroke from large-vessel stroke with >90% sensitiv-
ity and specificity (Figure 5). A separate 37-gene
profile differentiated cardioembolic stroke due to
atrial fibrillation from nonatrial fibrillation causes
with >90% sensitivity and specificity (Figure 6).
When these profiles were applied to patients with
cryptogenic stroke, 17% were predicted to be large
vessel and 41% to be cardioembolic stroke. Of the
cryptogenic strokes predicted to be cardioembolic,
27% were predicted to have atrial fibrillation
(Jickling et al, 2010). Thus, we have demonstrated
the feasibility of using gene expression to demon-
strate the causes of ischemic stroke, and to use these
profiles to predict the causes of cryptogenic stroke.
Markers versus mechanisms
The above descriptions outline the approach for
deriving biomarkers. However, for each analysis we
obtain a short list of genes for prediction and a long
RNA Expression in Blood Differentiates Different Causes
of Stroke in Humans
Figure 4 Cluster analysis of the 77 genes (analysis of variance
(ANOVA), P<0.05, fold change >1.5) that were differentially
expressed between cardioembolic and atherosclerotic stroke.
X axis shows each condition at 3, 5, and 24hours after the
ischemic stroke. Y axis shows individual genes. The color coding
indicates gene expression intensity, with red being high and
green being low. This figure is adapted from Xu et al (2008).
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example, after obtaining data from an experimental
data set (stroke) compared with controls, different
statistical approaches are used. First, the least
number of genes that best distinguish the groups
are determined using strict statistical cutoffs. Sec-
ond, the maximal number of genes/probes that
distinguish the two groups are derived using less
stringent statistical cutoffs (Figure 7). The least
number of genes is used for biomarkers and predic-
tion (diagnosis) (Figure 7). The large list of regulated
genes is used to derive the gene ontologies and the
known pathways and networks that differentiate the
two groups (Figure 7). These changes may represent
causes or effects related to the stroke, but none-
theless provide information regarding pathogenesis.
One of the important and difficult to grasp features
of these analyses is that there may be no best number
of classifier/biomarker/diagnostic genes. For example,
a panel of 25, 30, or 35 genes may all have a similar
sensitivity and specificity. This can explain why
different gene lists might be quite predictive in
different studies. Generally, too few genes or too
many genes can significantly decrease predictive
power.
A different approach is used for pathway analyses.
For most studies, a given level of significance is set
(corrected P<0.05 with a false-discovery rate of
5%—see below) coupled with a fold change cutoff,
which is usually >1.2 for blood studies (Jickling
et al, 2010; Stamova et al, 2010). Using this cutoff for
most of our stroke studies, one obtains hundreds of
genes/probe sets. These can then be used for most
pathway/gene ontology programs to determine if
there are more genes than expected by chance
expressed in a particular pathway. If there are too
many genes, the approach does not work well
because pathways are saturated. In addition, if there
Figure 5 (A) Hierarchical cluster plot of the 40 genes that were significantly different between cardioembolic stroke and large-vessel
stroke. Genes are shown on the Y axis and subjects are shown on the X axis. Red indicates a high level of gene expression and blue
indicates a low level of gene expression. Subjects cluster by diagnosis. (B) Principal components analysis of the 40 genes that
differentiated cardioembolic stroke from large-vessel stroke. Each sphere represents a single subject. The ellipsoid surrounding the
spheres represents 2 s.d. from the group mean. (C) Leave-one-out crossvalidation prediction analysis of the 40 genes found to
differentiate cardioembolic stroke from large-vessel stroke. The probability of the predicted diagnosis is shown on the Y axis. The
actual diagnosis is shown on the X axis, where patients with known cardioembolic stroke are shown on the left (top bracket), and
patients with known large-vessel stroke are shown on the right (top bracket). The probability of a predicted diagnosis of
cardioembolic stroke is indicated with green diamonds, and the probability of a predicted diagnosis of large-vessel stroke is indicated
with orange squares. Subjects with known cardioembolic stroke were predicted to have cardioembolic stroke for 69 out of 69
samples (100% correct prediction). Subjects with known large-vessel stroke were predicted to have large-vessel stroke for 29 out of
30 samples (96.7% correct prediction). A sample is considered misclassified if the predicted class does not match the known class
with a probability >0.5. This figure is adapted from Jickling et al (2010).
Molecular markers and mechanisms of stroke
FR Sharp et al
1520
Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1513–1531are too few it also does not work well since there are
too few genes per pathway. There are probably
statistical approaches for deriving the optimal num-
ber of genes for these pathway analyses that the
authors are not aware of.
Figures 8–11 provide examples of markers and
mechanisms derived from several of our microarray
studies. Figure 8 shows the derivation of markers
and their use to diagnose cryptogenic stroke (Jickling
et al, 2010). Using linear discriminant analysis (or
other methods like support vector machines or
k-nearest neighbors/prediction analysis of micro-
arrays) one can derive the 40 genes that best
differentiate cardioembolic stroke and large-vessel
stroke (Figure 8). Using these 40 genes and applying
them only to the patients with cryptogenic strokes,
one can again utilise linear discriminant analysis to
predict which cryptogenic strokes were cardioem-
bolic (41%) and which were due to large-vessel
disease (17%). This shows how biomarkers are used
for prediction (Jickling et al, 2010). The goal of a
biomarker prediction study is to derive the least
number of the best predictors to derive the best
sensitivity and specificity for the prediction in ques-
tion. This can be applied to any problem with stroke—
or any other medical condition for that matter.
Figure 9 shows how the genes regulated following
ischemic stroke change in the interleukin-1A and 1B
signaling pathways from 2 to 3hours (upper panel)
compared with 5hours following stroke (lower
panel). Interleukin-1 worsens stroke in most animal
models (Allan and Rothwell, 2003; Rothwell and
Luheshi, 2000). In humans, it is one of the mediators
of the febrile response, which may worsen stroke in
and of itself. There are few genes regulated between 2
and 3hours after stroke whereas by 5hours virtually
every gene in the pathway is regulated (Figure 9;
red=upregulated; green=downregulated). This is a
little misleading since changes were occurring before
3hours but these were too small for detection. The
data suggest that drugs acting on interleukin-1
pathways could be acting within the therapeutic
window for acute human ischemic stroke, i.e., 0 to
4.5hours.
Figure 6 (A) Cluster analysis of the 37 genes that were significantly different in subjects with cardioembolic stroke due to atrial
fibrillation compared with subjects with nonatrial fibrillation causes. Genes are shown on the Y axis and subjects are shown on the X
axis. Red indicates a high level of gene expression and blue indicates a low level of gene expression. (B) Principal components
analysis of the 37 genes that differentiated cardioembolic stroke due to atrial fibrillation from nonatrial fibrillation causes. Each
sphere represents a single subject. The ellipsoid surrounding the spheres represents 2 s.d. from the group mean. (C) Leave-one-out
crossvalidation prediction analysis of the 37 genes found to differentiate cardioembolic stroke due to atrial fibrillation from nonatrial
fibrillation causes. The probability of the predicted diagnosis is shown on the Y axis. The actual diagnosis is shown on the X axis,
where patients with known atrial fibrillation are on the left (top bracket), and patients with known nonatrial fibrillation stroke are on
the right (top bracket). The probability of a predicted diagnosis of stroke due to atrial fibrillation is indicated with green diamonds,
and the probability of a predicted diagnosis of nonatrial fibrillation stroke is indicated with orange squares. Subjects with known
cardioembolic stroke due to atrial fibrillation were predicted to have atrial fibrillation as a cause of stroke in 30 out of 30 samples
(100% correct prediction). Subjects with cardioembolic stroke due to nonatrial fibrillation causes were correctly predicted in 22 out
of 24 samples (91.7% correct prediction). A sample is considered to be misclassified if the predicted class does not match the
known class with a probability >0.5. The figure is adapted from Jickling et al (2010).
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differentially in cardioembolic versus large-vessel
stroke relate to different mechanisms (Xu et al, 2008).
For cardioembolic stroke, the main functions were
immune response, defense response, response to
biotic stimuli, and response to pathogens (Xu et al,
2008). This suggests that inflammation and perhaps
even infection might be important in these cardioem-
bolic strokes. In contrast, hemostasis, chemokine
activity, and related pathways were the highest
ranked functions for large-vessel atherosclerotic
stroke. This would be consistent with the observa-
tion that antiplatelet agents are useful in decreasing
risk from strokes due to large-vessel disease.
White-matter hyperintensities and
brain ischemia
RNA expression studies also offer the opportunity to
compare with other disease entities and mechanisms
shared or not shared with brain ischemia. For
example, we recently studied a group of elderly
patients with white-matter hyperintensities (WMH)
(Xu et al, 2010). White-matter hyperintensities are
areas of high signal detected by T2 and fluid-
attenuated inversion recovery sequences on brain
magnetic resonance imaging. Although associated
with aging and vascular risk factors, the pathogenesis
of WMH remains unclear. One postulated cause is
chronic ‘brain ischemia.’ To address this, 20 subjects
with extensive WMH (WMH+), 45% of whom had
Alzheimer disease, were compared with 18 with
minimal WMH (WMH), 44% of whom had Alzhei-
mer disease. RNA was processed on HU133 Plus 2.0
microarrays. In all, 241 genes were differentially
regulated (fold change >1.2, P<0.005) between the
groups. A cluster analysis separated the group with
extensive WMH from the group with minimal WMH
(Figure 11). Function analyses suggested that WMH-
specific genes were associated with oxidative
stress, inflammation, detoxification, and hormone
signaling, and included genes associated with oligo-
dendrocyte proliferation, axon repair, long-term
potentiation, and neurotransmission (Xu et al,
2010). Notably, only 4 of the 241 WMH genes were
previously identified in our studies outlined above
of ischemic stroke (Stamova et al, 2010; Xu et al,
2010). This does not exclude ischemia as a causal
factor in WMH, but it does suggest that there must be
differences between acute ischemic stroke and any
‘ischemia-related changes’ that might be associated
with WMH. The WMH study was important for
showing that the stroke-related genes probably are
not related to coincidental WMH; the WMH and
Alzheimer and ischemic stroke genes identified in
peripheral blood were different; and that WMH may
in fact be a discrete entity since a specific gene
expression profile can be associated with it in
peripheral blood.
Technical challenges associated with
RNA studies
The technical difficulties and multiple methodolo-
gical and analytical pitfalls associated with these
studies cannot be overemphasized. Moreover, the
chances for failure are high given the small groups
usually being studied, small biological changes that
require great technical rigor, and different statistical
approaches that can influence study findings.
For those beginning in the field it is critical to read
the many reviews that are now available and make
critical decisions based upon as much knowledge as
possible. Some of the decisions that we have made
Strategy for Markers vs Mechanisms
23,000 Genes
On the Microarray  
1355 Stroke vs Control
25 Best Classifier Genes 350 Pathway Genes
Biomarker Profile Networks
Mechanisms Diagnosis
Figure 7 Strategy for deriving gene lists to for prediction
(biomarker profile and diagnosis) versus lists to study pathways,
networks and mechanisms. Stroke versus controls produces a
large gene list using loose statistical criteria. Prediction
algorithms (e.g., linear discriminant analysis, support vector
machine and others) are used to derive the best classifier/
prediction genes, which are then applied to a second test set for
prediction. An intermediate statistical cutoff is used to generate a
list of hundreds of genes that can then be used for pathway, gene
ontology, and other analyses to assess pathways, networks, and
mechanisms.
Prediction of Cryptogenic Stroke
Cardioembolic vs Large Vessel 
LDA
40 genes
Cryptogenic Stroke
30% of all strokes
41% Cardioembolic 17 % Large Vessel
LDA LDA
Figure 8 An example of the derivation and use of genes for
prediction. Using linear discriminant analysis (LDA), the least
number of genes that best differentiate cardioembolic and large-
vessel atherosclerotic stroke are derived (n=40 genes). Using
these 40 genes in linear discriminant analysis, the causes of
strokes in cryptogenic stroke patients are predicted. Of the
cryptogenic stroke patients, 41% were predicted to be cardi-
oembolic and 17% were predicted to be large vessel. These data
are from Jickling et al (2010).
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Affymetrix arrays. Though expensive, the company
has remained in business where others have not.
This will be much less of an issue once RNA
sequencing is generally used (see below). There have
been numerous protocols for RNA isolation and
labeling. We have kept with large companies who
maintain and support their products with the highest
Figure 9 Signaling pathways for interleukin (IL)1A and IL1B at 2 to 3hours (upper panel) and at 5hours (lower panel) following
ischemic stroke in humans. Data are from Tang et al (2006).
Figure 10 Functional comparisons of cardioembolic stroke-specific genes versus atherosclerotic stroke-specific genes. The function
rank score (Y axis) is a log-transformed P value. The higher the score, the more significant is the functional pathway (shown on the Y
axis). The functions are on the X axis. Cardioembolic functions are in red and large-vessel atherosclerotic functions are in blue. This
figure is adapted from Xu et al (2008).
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does not cut corners on reagents. We have avoided
major protocol changes unless absolutely necessary.
Changes in the protocols that have been made
included a DNAase step in RNA isolation, and the
use of NuGEN reagents so that very small amounts of
RNA can be used for each array (Jickling et al, 2010;
Stamova et al, 2010; Xu et al, 2010). If one is
contemplating a preliminary study followed by a
confirmatory one, one must standardize all methods
and arrays across those two studies. Ideally, methods
used previously by others should be used if con-
firmation across studies is desired.
Though now well known in the microarray field,
the ‘batch effects’ problem is still a major one. This is
a problem where one set of samples is run together
and then compared with separate samples that are
also run together—often separated over some time—
or performed in different laboratories. The universal
experience is that it is difficult and can be impossible
to compare two different ‘batches.’ To combat the
batch problem, experimental and control samples
must be intermixed, and the samples should be run
in the same laboratory and preferably all run at a
single time. If samples are to be run at different times
or in different locations, there are only a few
available approaches.
One approach is to use a reference or standard
RNA sample with each batch (Walker et al, 2008).
The standard RNA sample is run each time the other
samples or groups of samples are run. Spiked RNAs
have been used in the past. However, this does not
solve the problem. For the control RNA samples, it is
critical that the source of the RNA be the same as the
source of the target samples (Walker et al, 2008). For
example, if ischemic stroke blood samples are
compared with control blood samples, then the
‘standard or reference RNA sample’ must be a human
blood sample that is identical for every batch and
that has been handled and processed in a way
identical to that used for the stroke/control samples.
This approach allows one to correct across samples
on a gene-by-gene basis using a Bayes approach we
have published (Walker et al, 2008). The within
batch version of this approach is called COMBAT
and is publicly available.
Another approach to the batch problem is to use
the reference gene approach that we have developed
(Stamova et al, 2009). This approach identifies a
group of genes that are expressed at similar levels
across control and experimental subjects. The con-
trol gene approach is similar to the principle applied
to reverse transcriptase PCR where a reference gene
is run at the same time as the target. The problem
with the control gene approach on arrays, however,
appears to be that even ‘within array variance’ can be
considerable (unpublished data). Rigorous internal
reference approaches need to be developed before
the results of the data described in this review can be
applied in the clinic.
Analytical issues also go beyond the correction for
batch effects. In the early gene expression studies of
blood, no attempt was made to account for covari-
ates. It has become quite clear, however, that age and
gender have large effects on gene expression in blood
(Figure 12) (Tang et al, 2004a,b,c, 2005). If there are
genetic differences in the cohort, then this alone may
segregate subjects based upon gene expression in
peripheral blood (Figure 12) (Tang et al, 2004c).
Because of the need to account for covariates,
analysis of variance approaches are more commonly
used now for the statistical analyses. Earlier statistics
were based upon permutation approaches, which
were excellent at distinguishing groups but often did
not account for covariates.
The next analytical task is to design the study so
that marker and mechanism analyses are clear-cut
and robust. The first tasks are to identify the
‘regulated genes’ between groups. This always
requires some sort of within and across chip normal-
ization—RMA, GCRMA, and others. The choice of
the normalization method depends upon the array
type, group preferences, study goals, and other
considerations (Mieczkowski et al, 2010; Millenaar
et al, 2006; Shedden et al, 2005; Zakharkin et al,
2005). The statistical criteria for selecting genes are
also goal dependent. Some studies have used fold
change cutoffs only (Shi et al, 2010), and others have
Figure 11 Cluster analysis of white-matter hyperintensity
(WMH)-associated genes for normal control subjects and
Alzheimer subjects. The 241 genes that were differentially
expressed in extensive WMH subjects (high WMH) versus
minimal WMH subjects (low WMH) were used for an
unsupervised Pearson cluster analysis (P<0.005 and fold
change >1.2). Individual genes (n=241) are shown on the X
axis and individual subjects (n=38) are shown on the Y axis.
Genes showing high expression are indicated in red and genes
with low expression are indicated in blue. Note that all of the
subjects with high WMH are clustered separately from low WMH
subjects; and that there is a specific gene expression profile for
each. Half of the high WMH subjects had Alzheimer disease
(AD) and half were cognitively normal. Half of the low WMH
subjects had AD and half were cognitively normal. This figure is
adapted from Xu et al (2010).
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et al, 2001). Both of these have weaknesses when
applied to studies of blood. Generally, some combi-
nation of fold change and a reasonable statistical
cutoff result in the most reliable changes of gene
expression for studies of blood (Guo et al, 2007; Shi
et al, 2010; Tibshirani et al, 2002; Tusher et al, 2001).
A great many issues revolve around the choice of
cutoffs, which include everything from a very strict
Bonferroni (correction for total number of compar-
isons) to a less stringent Benjamini–Hochberg false-
discovery rate (Benjamini et al, 2001; Hsueh et al,
2003; Reiner et al, 2003; Shi et al, 2010; Tan et al,
2006). The accepted ‘standard in the field’ is to use a
false-discovery rate of 5%, which means that a given
list of genes contains no more than 5% false
positives. Thus, for preliminary microarray studies
most investigators focus on pathways rather than
single genes. The only way to confirm a given gene in
a whole genome microarray study is to confirm it in a
second independent study.
Once regulated genes are identified, the tools for
deriving biomarkers are excellent. These include
prediction analysis of microarrays, support vector
machine, linear discriminant analyses, machine
learning. and a host of others (Shi et al, 2010).
Methods of assessing sensitivity and specificity
using receiver operating curves and other approaches
are generally used by many and are readily available
in various public and private software packages.
What is less clear is how ‘to do’ the pathway and
network analyses. There are many versions of these
approaches—from known protein–protein interac-
tion databases, to information processing-relational
databases. One can also assess whether given lists of
genes are associated with specific pathways, gene
ontologies (molecular function, biological process,
cellular compartment), have overrepresentation of
transcription factor binding sites, regulated by
specific microRNAs, have specific chromosomal
distribution, or have other biological features that
make them particularly interesting or relevant for a
given question (Bammler et al, 2005; Draghici et al,
2003; Hedegaard et al, 2009). Even identifying genes
associated with a specific cell type in blood may
provide enormous mechanistic information, for ex-
ample Tcells versus B cells versus platelets (Du et al,
2006; Xu et al, 2008). At the present time, these
approaches help the researcher distill a very large
amount of data into a single word or phrase. They
still need to be supplemented by an in-depth review
of the literature for each question and study.
Most microarray studies, particularly those of
blood, have not replicated single genes. This may
relate to the possibility that there may not be a
perfect set of predictors for any condition. That is, in
our recent replication studies compared with our
previously published studies, two different sets of
genes predicted the previous study with >80%
sensitivity and specificity, whereas because of the
statistical design predicted the current study with
>90% sensitivity and specificity (Jickling et al, 2010;
Stamova et al, 2010). Finally, there may be hundreds
of predictive genes, and the best predictors might
actually vary over different populations at different
times.
There are several approaches to validating micro-
array studies. First, virtually every array study now
derives a set of gene predictors and then uses these to
perform ‘crossvalidation’ on the same cohort. If this
does not produce >80% sensitivity and specificity,
then the prospects for these predictors being useful
and replicable are poor. In addition, this is not an
acceptable method for accounting for multiple
comparisons since it tests the predictors on the gene
set from which it was derived.
In order to account for multiple comparisons, the
traditional approach is to develop a gene expression
profile in a ‘training cohort’ and then validate it in a
‘test cohort’ that is independent of the first. This
basic principle is applied to all whole genome
studies or any study where multiple parameters are
studied.
Currently, the most common way of performing
validation studies is to design a study with two
cohorts. In the first cohort, the disease of interest is
compared with controls and a gene profile derived
from this comparison. This gene profile is then used
on the second cohort in the same study to predict
who has the disease of interest (or other variable) or
who is a control. This approach I will refer to as a
‘within study with two cohorts’ approach. Though
this approach demonstrates that the predictors are
reliable and not false positives, the approach does
not necessarily account for the problem of batch or
between study comparisons. For the within study
C
Future of  RNA Expression in Stroke
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 RNAs  (lncRNAs) C A
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￿  Small interfering RNAs (siRNAs)
￿ microRNAs  (miRNAs)
￿  PIWI-interacting RNAs (piRNAs)
￿ Promoter-associated  RNAs
   (PARs)
￿  Small nucleolar RNAs (snoRNAs)
￿  X-inactivation RNAs (xiRNAs) MF
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Figure 12 Future studies of RNA expression in blood of subjects
with stroke will investigate the effects of age, gender, race,
underlying genetic differences in coding and noncoding RNAs.
The role of alternative splicing is likely to revolutionize these
analyses. Age: A, adults; C, children. Gender: F, females; M,
males. Genetics: C, controls; D, Down syndrome; NF, neurofi-
bromatosis; TS, tuberous sclerosis. Figures are adapted from
Tang et al (2004b,c).
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intermix the two cohorts and the control and
experimental samples to eliminate or decrease batch
effects. Thus, this approach does not address the
question of whether the predictors will work across
different studies performed on different cohorts at
different sites or at different points in time.
The only way to prove predictors is to use a ‘two
study two cohort approach.’ For this approach, the
first study uses two cohorts: a gene profile is derived
from the training cohort and this profile is then used
to predict the individuals in the second ‘test cohort.’
Once done, an independent study is performed: the
gene profile from the previous study is used to
predict the individuals in this second study, blinded
to the clinical disease group. What if the second
study fails? Though it is not entirely clear how to
solve this, potentially taking half of the individuals
in each study to derive a profile for the training set
could be used to predict the other half of the
individuals. Alternatively, combining the gene pro-
files in both studies might be successful for predict-
ing subjects in a third study. The reason for
performing a two study–two cohort study is to
absolutely ensure that the predictors were not
dependent upon an unrecognized batch effect or
unrecognized bias.
Role of reverse transcriptase
polymerase chain reaction and future
of isolating single cell types
The majority of initial preliminary studies have used
microarrays because they can survey all of the known
RNAs. It is still not clear what platform is best for
confirming a predictor set of genes derived from a
‘training set’ of individuals on the ‘test set’ of
individuals. This could be done using microarrays,
reverse transcriptase PCR, Nanostring, next genera-
tion sequencing or other emerging technologies.
Using microarrays has the advantage of using the
same platform to replicate using the same platform
the genes were derived from. However, PCR has the
advantage of providing a technical replication,
focusing the study just on the predictor set of genes
to markedly decrease multiple comparison correc-
tions, and precisely identify the RNA of a given gene
using specific primers for a gene or exon. The
eventual platform that might be used for clinical
assessments is unclear since PCR on a large number
of genes is still costly, microarrays continue to evolve
and new technologies like Nanostring and Next
Generation Sequencing are providing viable alter-
natives.
Most of our own work has focused on whole blood
obtained using PAXgene tubes because of the ease of
obtaining samples, storing them frozen and proces-
sing afterwards. One disadvantage of this approach is
that a large portion of the RNA is accounted for by
globin so that low abundance RNA transcripts tend
to be lost. There are globin reduction methods,
which have improved over the years and are
commercially available. We have not used these
because our preliminary studies had not used globin
reduction and early globin reduction methods pro-
duced variable results. If globin reduction is to be
used, reproducibility and reliability of results needs
to be confirmed.
The major disadvantage of PAXgene tubes, how-
ever, is that whole blood is assessed. This may be
adequate for biomarkers, but is woefully far from
understanding mechanisms related to different cell
types in blood. The future will require isolation of
individual cell types including neutrophils, B and T
lymphocytes, monocytes and their many subtypes.
We and others have published gene expression
profiles for these cell types (Du et al, 2006;
Kobayashi et al, 2007; Kotz et al, 2010; Robbins
et al, 2008; Wong et al, 2010). The potential problem
with these studies is that isolation may affect gene
expression (Holmes et al, 2009; Kotz et al, 2010; Lee
et al, 2010; Shim et al, 2010). This may be solved by
microfluiditic devices that use cell-specific antibo-
dies that isolate specific cell types at the bed side
(Kotz et al, 2010).
Future of RNA profiling—exon arrays,
splicing, next gen RNA sequencing
Even given the above problems, gene expression
studies at the very least will provide enormous
insights into the pathophysiology of stroke. Though
not reviewed here because of space, microRNA
studies of blood and brain, are providing novel
insights into how large groups of genes are regulated
following brain ischemia (Dharap et al, 2009;
Jeyaseelan et al, 2008; Liu et al, 2010; Reid et al,
2010; Tan et al, 2009). A number of studies of gene
expression related to atherosclerotic plaques have
been published and support the inflammatory nature
of these lesions, and provide insights into additional
pathways associated with high-risk lesions (Faber
et al, 2002; Gagarin et al, 2005; Vemuganti and
Dempsey, 2005). Ongoing studies in our laboratory
and others are assessing subarachnoid hemorrhage,
arteriovenous malformations, intracerebral hemor-
rhage, lacunar stroke (Jickling et al, submitted for
publication), transient ischemic attacks (Zhan et al,
submitted for publication), and risk of stroke from
transient ischemic attacks, effects of gender on gene
expression, and the correlation between gene ex-
pression and CIMT (carotid intima-media thickness),
which is an index of risk of vascular disease
including stroke (Turner et al, 2011b).
Not considered in this review is the potential
impact of exon arrays and next generation RNA
sequencing (Taub et al, 2010). Current exon arrays
allow one to assess expression of individual exons,
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(Tian et al, 2010, 2011). This is of great interest since
exon splicing accounts in part for diversity among
cell types and organs. Since there appear to be types
of alternative splicing that can be specific for certain
tumor types (Werner, 2010), it is possible that the
immune response to brain injury might be associated
with organ and perhaps even disease-specific alter-
native splicing due to the cell signaling that is
specific for immune cells’ response to brain ischemia
(Courtney et al, 2010). These studies have yet to be
done in stroke in part because they require even more
complex and expensive resources.
Microarrays may eventually be replaced by next
generation sequencing methods (RNA sequencing) to
evaluate gene expression (Hawkins et al, 2010). With
this technology, the entire transcriptome (RNAs) of a
given individual can be sequenced (Werner, 2010). In
theory, alternative splice variants of a given RNA can
be quantified, as can the expression at the individual
exon level (Hawkins et al, 2010; Werner, 2010). In
addition, it will be possible to examine noncoding
RNAs, which include the recently discovered micro-
RNAs (Werner, 2010). The names of the many more
noncoding RNAs are listed in Figure 12—with the
realization that most of the genome codes for RNAs
that are not translated into proteins, but instead
likely serve regulatory functions many of which are
still unknown. This exploding field will likely fuel
disease-related research (Hawkins et al, 2010). This
may also apply to different types of brain injuries
where immune-specific splicing or types of noncod-
ing RNA regulation will be specific for each type of
brain injury (Hawkins et al, 2010).
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